Sartorius Stedim Biotech (SDMHF) Set to Announce Quarterly Earnings on Thursday

Sartorius Stedim Biotech (OTCMKTS:SDMHF) is expected to be issuing its results before the market opens on Thursday, October 22nd. Analysts expect the company to post earnings of $1.37 per share and revenue of $857.36 million for the quarter.

Sartorius Stedim Biotech Stock Performance

Sartorius Stedim Biotech stock opened at $235.00 on Tuesday. Sartorius Stedim Biotech has a fifty-two week low of $178.30 and a fifty-two week high of $264.30. The firm’s 50-day simple moving average is $228.79 and its 200 day simple moving average is $210.06.

Analyst Ratings Changes

Separately, UBS Group upgraded Sartorius Stedim Biotech to a “buy” rating in a research note on Thursday, August 20th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sartorius Stedim Biotech has a consensus rating of “Moderate Buy”.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech SA is a France-based provider of technologies and services used by the biopharmaceutical industry. The company supports the development and manufacture of biologic medicines, including vaccines, therapeutic proteins, and other advanced biological products.

Its portfolio includes single-use bioprocessing equipment and consumables, bioreactors and fermentation systems, filtration and purification technologies, fluid-management products, cell-culture solutions, and laboratory instruments.